BioWorld Asia

Dec. 17, 2003

Acambis Files 'First-Ever' BLA: Arilvax Vaccine In Yellow Fever

Acambis plc filed a biologics license application seeking approval of Arilvax as a vaccine to prevent yellow fever. (BioWorld International) Read More

Arpida Moving Iclaprim Into Phase III Trial, Seeking EUR25M

Trial To Test Recombinant Poxvirus Vaccine In Malaria

Genmab Stops HuMax-CD4 Development In Psoriasis

Ingenium Plans Growth After Third Round Brings In EUR13.8M

Benitec Settles ddRNAi Dispute, Raises A$10.9M To Fund Growth

Faust Pharmaceuticals Acquires Euroclide, Seeks EUR12M Funding

Innate Pharma, Novo Nordisk In Cancer Immunotherapy Deal

Novacea Licenses Cancer Drug From KuDOS Pharmaceuticals

London Cluster Growing But Lab Space Shortage Impedes

EU Moving Closer To New Rules On Pharmaceuticals, Tissues, Cells

Industry Representatives Meet In Israel To Discuss Bioengineering

Fulcrum To Help Addex Build Internal Clinical Development

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for April 1, 2026.

Emerging therapeutic strategies for Parkinson’s at ADPD 2026

BioWorld

Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...

With improved technologies, biomarkers, failed drugs may come into their own

BioWorld

At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...

Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

Small-molecule TREM2 agonist advances to treat Alzheimer’s

BioWorld Science

Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 31, 2026